The Department of Veterans Affairs says it negotiated $10.44 billion off the price of prescription drugs so far in fiscal year 2026, the largest total the agency says it has recorded for a single year. VA Secretary Doug Collins tied the number to tougher negotiating with drug manufacturers, saying the department is delivering what he called “huge wins for Veterans and taxpayers.” For a household built around a veteran who depends on VA pharmacy benefits, the figure is the agency’s own tally of what it says it kept out of its drug budget — not a number an outside auditor has checked.
VA published the total in an August 13 press release and has not broken it down by drug, contract, or manufacturer. The number covers only part of a fiscal year that runs from October 1 through September 30 — roughly ten and a half months of fiscal 2026 had passed by the time VA announced the figure — so whatever VA eventually reports as the full-year total is likely to be higher.
A Three-Year Climb From $5.23 Billion to $10.44 Billion
VA’s own reporting shows the claimed savings roughly doubling over three fiscal years. The agency says it achieved $5.23 billion in pharmaceutical price reductions in fiscal year 2024, $7.99 billion in fiscal year 2025, and $10.44 billion so far in fiscal year 2026 — a total the department describes as nearly double what it says was reached in the final full fiscal year of the Biden administration.
VA has not published a line-by-line accounting of how the number is calculated or whether it reflects manufacturer rebates, generic substitutions, renegotiated supply contracts, or some combination of the three. In its own description, the agency ties the increase to an effort launched under the current administration that focuses on the pharmaceuticals VA uses most often to treat veterans, with the stated goal of freeing up money to treat more veterans and to cover newer, more expensive therapies earlier in their product life cycle.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
New Enrollment Numbers Arrived Weeks After the Savings Claim
Less than three weeks after the pharmaceutical figure was announced, VA reported that more than 250,000 new veterans had enrolled in VA health care so far in 2026, up from the more-than-215,000 figure the department cited in the August drug-pricing release. VA credits the growth to expanded outreach toward veterans who were not previously enrolled in VA care and benefits, and it says the newly enrolled group has already completed or scheduled more than 1.4 million medical appointments, including more than 300,000 mental health visits and more than 12,000 emergency care visits.
The two announcements come from the same VA press office within weeks of each other, and the department frames both as evidence that recent changes are reaching more veterans. Neither release ties the drug-price total directly to the enrollment total — VA has not said how much of the $10.44 billion, if any, is being spent on the newly enrolled group specifically. The two releases also do not fully agree with each other: the August release counted 40 new VA health care facilities opened since January 20, 2025, while the September release put the same count at 41. VA has not explained the change.
A Benefits Backlog VA Says Is Shrinking Too
VA has pointed to a separate figure as part of the same broader claim of progress: a backlog of disability compensation and pension claims that the department says is down more than 70% since January 20, 2025, after growing 24% during the prior administration. VA’s own live claims tracker shows the total backlog of disability compensation and pension claims — the rating-bundle claims that require development and a decision from a VA claims processor — at 71,279 as of its most recent update in late August.
That backlog figure measures a different part of VA’s operations than the pharmaceutical savings claim does: how quickly benefits claims move through the system rather than how much the agency pays for medication. VA has grouped both figures together in its public messaging as evidence of broader operational change, even though the underlying data comes from separate parts of the department and is reported on separate schedules.
VA has also said the backlog fell below 70,000 claims in June 2026 for the first time since 2020. Two months later, the department’s own live tracker put the total back above that line, at 71,279, a reminder that a weekly claims count can move in both directions even while VA describes the longer trend as improving.
What VA Health Care Actually Pays For
The pharmacy savings apply to the same VA health care system that covers primary care checkups, specialist appointments, home health and geriatric care, medical equipment, prosthetics, and prescriptions for enrolled veterans. VA’s own health care portal lays out how eligibility and enrollment priority groups work and how a veteran applies online, by phone, by mail, or in person. Whether a particular medication costs less because of the price reductions VA is reporting would depend on which drug is prescribed and which VA facility fills it — details the agency has not published alongside the $10.44 billion figure.
A Number the Agency Reports, Not One an Outside Auditor Has Certified
Every figure in VA’s account — the $10.44 billion in price reductions, the enrollment growth, and the shrinking claims backlog — comes from VA’s own press office and has not been verified in these announcements by the Government Accountability Office, VA’s Office of Inspector General, or another independent body. That does not make the number false. It means the $10.44 billion is presented, in VA’s own words, as what the department “secured” and is “benefitting from,” a self-reported measure of negotiating results rather than an audited expense reduction. A veteran or family member weighing what the savings mean for their own care is left with the agency’s own account until an outside review, if one happens, either confirms or revises the total.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
